For melanoma patients whose tumors have been surgically removed, the question is whether the cancer will come back. On October 24, at the European Society for Medical Oncology (ESMO) Congress in Madrid, Merck and Moderna reported that a personalized mRNA therapy, added to the standard immunotherapy Keytruda, lowered that risk by 42 percent in a phase 3 trial. The result has been accepted for publication in The New England Journal of Medicine, according to the companies.

What was tested

The therapy, intismeran autogene (also known as mRNA-4157 or V940), is built for each patient. A sample of the person's tumor and normal tissue are sequenced to identify mutations unique to the cancer, and the company then makes an mRNA molecule coding for up to 34 of the resulting neoantigens, per Merck. Once injected, the body's cells read the mRNA and present those cancer-specific fragments to the immune system, which is meant to learn to attack cells that carry them.

The INTerpath-001 trial enrolled 1,137 patients with completely resected stage IIB to IV melanoma. They were randomized two to one to receive intismeran every three weeks for up to nine doses plus Keytruda (pembrolizumab) for about a year, or a placebo plus Keytruda, in a double-blind design. The primary endpoint was recurrence-free survival.

The headline numbers

After a median follow-up of 24.6 months, the combination reduced the risk of recurrence or death by 42 percent compared with Keytruda alone (hazard ratio 0.58, 95 percent confidence interval 0.45 to 0.75), according to the companies. The risk of distant metastasis or death fell by 38 percent (hazard ratio 0.62).

In absolute terms, 82.2 percent of patients on the combination were alive without recurrence at two years, compared with 70.0 percent on Keytruda alone, a gap of 12.2 points. Two-year distant-metastasis-free survival was 88.5 percent versus 80.2 percent. Median recurrence-free survival had not been reached in either group, which means more than half of patients in both arms had not relapsed.

Overall survival was not yet mature. The companies said they observed a favorable trend, and that the trial continues. That is the missing number, and nothing in the release can substitute for it.

A benefit that took six months to show

The most interesting detail is about timing. In the first six months, while patients were receiving the intismeran series, the combination did no better than Keytruda alone, with a hazard ratio of 0.99. After six months, in a pre-specified sensitivity analysis, the risk of recurrence or death was 58 percent lower (hazard ratio 0.42), and the risk of distant metastasis or death was halved.

A delay of this kind is not unusual for immune therapies, which need time to train and expand T cells. It does mean the headline 42 percent blends a period with no difference and a period with a large one. A separate pre-specified analysis that excluded patients who did not receive at least one dose as planned gave a 49 percent reduction (hazard ratio 0.51). These are sensitivity analyses, not the primary endpoint, so they illustrate the effect more than they establish it.

Side effects

Treatment-related adverse events occurred in 95.8 percent of patients on the combination and 90.0 percent on Keytruda alone, per the companies. Serious grade 3 to 5 events were similar: 14.2 percent versus 13.4 percent. The most common events in the combination arm were fever (52.2 percent), injection-site pain (51.0 percent) and fatigue (38.5 percent). The companies reported no new safety signals.

That profile suggests the add-on mostly brings short-lived reactions that resemble those of other injected immune therapies. It also shows why the numbers need independent review. The adverse-event data come from the sponsors' own analysis.

What remains unproven

Several caveats apply. The results are company-reported, though the journal acceptance means peer review is under way. Overall survival is immature, and recurrence-free survival is an earlier measure that does not always translate into longer life, as with the FDA's Tecentriq approval for stage III colon cancer, where overall survival had not yet been shown to differ. By contrast, a drug like daraxonrasib for pancreatic cancer was backed on survival already measured. The standard of proof for each is different.

The release also says nothing about how benefit varies by stage, and it does not address how long each personalized dose takes to make or what the therapy would cost. For a treatment built from each patient's own tumor, those practical questions matter as much as the hazard ratio. Merck and Moderna say they are engaging with regulators, which does not mean approval is near.

Why it matters

If overall survival confirms the trend, this would be among the first phase 3 successes for an individualized mRNA cancer therapy, and Merck and Moderna describe it as the first showing a clinically meaningful gain over Keytruda alone in resected melanoma. Professor Georgina Long, who led the trial and directs medical oncology at Melanoma Institute Australia, said the findings support tailoring treatment to the mutational signature of each patient's tumor.

The program does not stop at melanoma. The companies are running nine phase 2 and 3 trials across tumor types, including three phase 3 trials in non-small cell lung cancer. Melanoma was more than 338,000 new cases worldwide in 2024, according to the release, and recurrence most often appears within two years of surgery, which is why an adjuvant benefit that emerges after six months could matter.

The next number to watch is not another hazard ratio. It is overall survival from the same trial, because that is where a lower relapse rate either turns into longer lives or turns out to be a delay.

---